Category Archives: Newsletter

Volume 4, May 2018

The Importance of Diversity in Clinical Research
Despite what is known about how certain groups of people may respond differently to disease; traditionally, the majority of cardiovascular clinical research study participants are white men. Increasing diversity in clinical research studies is a priority for the Food and Drug Administration and the ADAPTABLE team in making sure results provide evidence that is relevant and helpful to a wide range of people. Diversity in clinical research studies helps ensure that the results will have an impact on the people the study is intended to help.





Volume 3, February 2018

Celebrating Your Heart and Heart-Health Awareness & American Heart Month.
Heart disease is the leading cause of death for American women and men, responsible for one in four deaths in the U.S. According to the Centers for Disease Control and Prevention, someone in the U.S. has a heart attack every 40 seconds, and every year 790,000 Americans have a heart attack. For 210,000 people this is their second heart attack. Unfortunately, once you have had a heart attack, your chance of having another one increases. The good news is that there are actions you can take to protect your heart.

VIEW NEWSLETTER FOR February 2018 (pdf)



Volume 2, October 2017

Better health outcomes for all when patients partner with researchers.
This motto crafted by the Adaptors, ADAPTABLE’s patient partners, reflects how patient participation in research can help answer health questions that matter most to patients and their doctors. The Adaptors’ motto is part of the Hero’s Journey Art Project, a touring art exhibit developed by Eli Lilly to honor clinical trial participants and raise awareness of clinical research.

VIEW NEWSLETTER FOR October 2017 (pdf)


Volume 1: Welcome, June 2017

Thank you for your participation in the ADAPTABLE Study.

Your involvement in this research study will help us to answer a simple, but extremely important question—what is the best aspirin dose (81 mg or 325 mg) for patients with heart disease? In addition to answering the aspirin-dose question, ADAPTABLE is building a community where patients are partners throughout the research process.



tertiary sidebar container